S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

CPIX Cumberland Pharmaceutical Inc

2.26

0.01 (0.44%)

01 Feb 2025 - Closed

Delayed by 15 minutes

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Cumberland Pharmaceutical (NASDAQ:CPIX)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Cumberland Pharmaceutical Charts.

Cumberland Pharmaceutical (NASDAQ:CPIX)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Cumberland Pharmaceutical Charts.

Cumberland Pharmaceutical Inc News

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Friday 31 January 2025 (1 day ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 31 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 31 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 10 December 2024 (2 months ago) • Edgar (US Regulatory)

FDA APPROVES ACETADOTE® sNDA
Tuesday 10 December 2024 (2 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Saturday 9 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 8 November 2024 (3 months ago) • Edgar (US Regulatory)

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
Friday 8 November 2024 (3 months ago) • PR Newswire (US)

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Thursday 7 November 2024 (3 months ago) • PR Newswire (US)

More Cumberland Pharmaceutical Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions